Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors.

Zulfiqar B, Mahroo A, Nasir K, Farooq RK, Jalal N, Rashid MU, Asghar K.

Onco Targets Ther. 2017 Jan 21;10:463-476. doi: 10.2147/OTT.S119362. eCollection 2017. Review.

2.

Docking Studies and Molecular Dynamic Simulations Reveal Different Features of IDO1 Structure.

Greco FA, Bournique A, Coletti A, Custodi C, Dolciami D, Carotti A, Macchiarulo A.

Mol Inform. 2016 Sep;35(8-9):449-59. doi: 10.1002/minf.201501038. Epub 2016 Jul 19.

3.

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Mar 10;5(6):e1149674. doi: 10.1080/2162402X.2016.1149674. eCollection 2016 Jun. Review.

4.

Targeting the indoleamine 2,3-dioxygenase pathway in cancer.

Moon YW, Hajjar J, Hwu P, Naing A.

J Immunother Cancer. 2015 Dec 15;3:51. doi: 10.1186/s40425-015-0094-9. eCollection 2015. Review.

5.

Trial watch: IDO inhibitors in cancer therapy.

Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 15;3(10):e957994. eCollection 2014 Nov. Review.

6.

The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1.

Flick HE, Lalonde JM, Malachowski WP, Muller AJ.

Int J Tryptophan Res. 2013 Aug 19;6:35-45. doi: 10.4137/IJTR.S12094. eCollection 2013.

7.

Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenase.

Marwaha A, White J, El Mazouni F, Creason SA, Kokkonda S, Buckner FS, Charman SA, Phillips MA, Rathod PK.

J Med Chem. 2012 Sep 13;55(17):7425-36. doi: 10.1021/jm300351w. Epub 2012 Aug 21.

8.

Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer.

Akinboye ES, Rosen MD, Denmeade SR, Kwabi-Addo B, Bakare O.

J Med Chem. 2012 Sep 13;55(17):7450-9. doi: 10.1021/jm300426q. Epub 2012 Aug 16.

9.

Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases.

Li L, Huang L, Lemos HP, Mautino M, Mellor AL.

Front Immunol. 2012 May 11;3:109. doi: 10.3389/fimmu.2012.00109. eCollection 2012.

10.

2-(5-Fluoro-2,3-dioxoindolin-1-yl)ethyl 4-methyl-piperazine-1-carbodithio-ate.

Wang Y, Lin HH, Cao SL.

Acta Crystallogr Sect E Struct Rep Online. 2012 Jan;68(Pt 1):o94-5. doi: 10.1107/S1600536811052494. Epub 2011 Dec 10.

11.

Crinum latifolium leave extracts suppress immune activation cascades in peripheral blood mononuclear cells and proliferation of prostate tumor cells.

Jenny M, Wondrak A, Zvetkova E, Tram NT, Phi PT, Schennach H, Culig Z, Ueberall F, Fuchs D.

Sci Pharm. 2011 Apr-Jun;79(2):323-35. doi: 10.3797/scipharm.1011-13. Epub 2011 Apr 5.

12.

2-(2,3-Dioxoindolin-1-yl)ethyl 4-(4-nitro-phen-yl)piperazine-1-carbodithio-ate.

Wang Y, Wan CQ, Cao SL, Zheng T.

Acta Crystallogr Sect E Struct Rep Online. 2010 Aug 11;66(Pt 9):o2243. doi: 10.1107/S1600536810030618.

13.

Benzyl N-[2-(1H-indol-3-yl)eth-yl]dithio-carbamate.

Vembu N, Fronczek FR, Petit C, Devocelle M.

Acta Crystallogr Sect E Struct Rep Online. 2007 Dec 18;64(Pt 1):o288-9. doi: 10.1107/S1600536807066524.

14.

Beyond immunosuppression: reconsidering indoleamine 2,3-dioxygenase as a pathogenic element of chronic inflammation.

Muller AJ, Mandik-Nayak L, Prendergast GC.

Immunotherapy. 2010 May;2(3):293-7. doi: 10.2217/imt.10.22. No abstract available. Erratum in: Immunotherapy. 2010 Jul;2(4):590.

15.

Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase.

Metz R, Duhadaway JB, Rust S, Munn DH, Muller AJ, Mautino M, Prendergast GC.

Mol Cancer Ther. 2010 Jun;9(6):1864-71. doi: 10.1158/1535-7163.MCT-10-0185. Epub 2010 Jun 8.

16.

Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation.

Ghosh AK, Takayama J, Rao KV, Ratia K, Chaudhuri R, Mulhearn DC, Lee H, Nichols DB, Baliji S, Baker SC, Johnson ME, Mesecar AD.

J Med Chem. 2010 Jul 8;53(13):4968-79. doi: 10.1021/jm1004489.

17.

Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate.

Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC.

Cancer Res. 2010 Mar 1;70(5):1845-53. doi: 10.1158/0008-5472.CAN-09-3613. Epub 2010 Feb 16. Erratum in: Cancer Res. 2010 Apr 15;70(8):3414.

18.

Substrate-protein interaction in human tryptophan dioxygenase: the critical role of H76.

Batabyal D, Yeh SR.

J Am Chem Soc. 2009 Mar 11;131(9):3260-70. doi: 10.1021/ja807969a.

19.

Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.

Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, Prendergast GC, Muller AJ.

J Med Chem. 2008 Aug 28;51(16):4968-77. doi: 10.1021/jm800512z. Epub 2008 Jul 30.

20.

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

Kumar S, Malachowski WP, DuHadaway JB, LaLonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ.

J Med Chem. 2008 Mar 27;51(6):1706-18. doi: 10.1021/jm7014155. Epub 2008 Mar 5. Erratum in: J Med Chem. 2008 Nov 27;51(22):7325.

Supplemental Content

Support Center